Building a hematopoietic cell transplantation outcomes registry in Mexico

The aim of this study was to assess the feasibility of hematopoietic cell transplantation (HCT) data collection using an electronic platform at Mexican centers. Four public centers performing HCT in adults were included. A cloud-based electronic platform in Spanish was developed to allow real-time r...

Full description

Saved in:
Bibliographic Details
Published in:Bone marrow transplantation (Basingstoke) 2020-12, Vol.55 (12), p.2279-2285
Main Authors: Rivera-Franco, Monica M., Leon-Rodriguez, Eucario, Gómez-Almaguer, David, Gutiérrez-Aguirre, Cesar H., Valero-Saldaña, Luis M., Acosta-Maldonado, Brenda L., Limón-Flores, Jose A., Pérez-Lozano, Uendy
Format: Article
Language:English
Subjects:
692/308/174
692/700/228
Adult
Autografts
Cell Biology
Cloud computing
Data collection
Demographic variables
Electronic health records
Electronic medical records
Feasibility
Hematology
Hematopoietic Stem Cell Transplantation
Hematopoietic stem cells
Humans
Internal Medicine
Leukemia
Medicine
Medicine & Public Health
Mexico
Middle Aged
Multiple Myeloma
Patients
Physicians
Public Health
Registries
Stem cell transplantation
Stem Cells
Transplantation
Transplantation Conditioning
Transplantation, Autologous
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to assess the feasibility of hematopoietic cell transplantation (HCT) data collection using an electronic platform at Mexican centers. Four public centers performing HCT in adults were included. A cloud-based electronic platform in Spanish was developed to allow real-time registration of demographic, clinical, and outcomes variables. Data were obtained from paper and electronic medical records and institutional databases. Data managers were hired to perform the collection. Data from January 2015 to December 2018 were retro and prospectively collected during a 10-month period. From 2015 to 2018, 473 HCT were performed. Most were autologous (55%). Patients undergoing autologous HCT had the highest median age (49 years) compared with patients undergoing allogeneic (34 years) or haploidentical HCT (29 years). The most common underlying disease for autologous HCT was multiple myeloma. Acute leukemias were the most common diagnoses among allogeneic and haploidentical HCT recipients. Two-year nonrelapse mortality was 2.5%, 18%, and 18% for autologous, allogeneic, and haploidentical HCT, respectively. We determined it was feasible to start a multicenter collaborative study in Mexico as it was very well received by the physicians and it can lead to the creation of a Mexican HCT Registry in the near future.
ISSN:0268-3369
1476-5365
DOI:10.1038/s41409-020-0944-z